Skip to main content
SpringerLink
Log in

Celgene Europe Ltd. has withdrawn its application to CHMP to use lenalidomide [Revlimid] for maintenance treatment of newly diagnosed

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Withdrawal of the application for a change to the marketing authorisation for Revlimid (lenalidomide). Internet Document: [3 pages], 2 Jul 2012. Available from: URL: http://www.ema.europa.eu

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Celgene Europe Ltd. has withdrawn its application to CHMP to use lenalidomide [Revlimid] for maintenance treatment of newly diagnosed. React. Wkly. 1415, 4 (2012). https://doi.org/10.2165/00128415-201214150-00012

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201214150-00012

Keywords

Search

Navigation